|
|
|
© 2025 Octapharma USA, Inc.
All Rights Reserved
Todos los derechos reservados
|
Mike’s family emigrated from Russia, through Austria, then Italy, where he was born, before settling in the United States in Brooklyn, New York. His severe hemophilia A was diagnosed at birth in Italy when it was discovered that his blood would not clot. Although unaware of any family history of bleeding disorders, Mike jokes that perhaps he is a descendent of the Romanovs, the famous Russian dynasty often associated with genetic transmission of hemophilia. “Who knows? I could be related to a czar.” Royal inheritance or spontaneous onset – whatever the genesis – his hemophilia has been the key to making him the person he is today.
Mike grew up suffering spontaneous bleeds into his knee and hip, developing issues with those joints. He was constantly in and out of hospitals, which was very hard on everyone. Until his mother learned to do infusions, a nurse would come to his home to treat his bleeds on an on-demand basis. Then his mom trained to be a phlebotomist and took over with prophylactic infusing for Mike. When he was about 11 years old, the family moved to New Jersey. There he got interested in sports and exercise, particularly basketball, and he wanted to be more independent and active. He also wanted to go on a trip he was invited on by his friend’s family. His mom said yes, but only under the condition that he first learn to self-infuse so he could continue with his treatment regimen while away. “That was all the encouragement I needed. Once I learned to self-infuse, life just got better.” Today he maintains a healthy lifestyle, loves exercise, travel, spending time with family and friends, and following football. A newlywed, Mike enjoys life with his wife Brianna and twin dachshund pups Carson and Remi (“my babies”) and is halfway through his goal of visiting each one of the 32 NFL stadiums in the nation. He remains 100% committed to his health and well-being. “I believe in holistic self-care and in prophylaxis – I haven’t incurred more joint damage over the past 20 years.”
Because of his own experiences with joint damage and physical limitation as well as his love of exercise, Mike became very interested in biology and the human body, eventually graduating with a doctorate in Physical Therapy and developing a private practice with Alliance Orthopedics. “I see patients with orthopedic and neurological issues, and see many people with joint damage resulting from a bleeding disorder. Although many people with problem joints are steered to pain medication and joint replacement, I prefer to address these issues in a holistic manner, focusing on targeted exercises, manual manipulation to reduce scar tissue, kinesiological taping, orthotics, and other more natural interventions to reduce pain, swelling, and the possibility of serious long-term damage. My goal is to get the best results in the least invasive fashion.” In fact, it was his interest in natural treatments that got Mike interested in NUWIQ®. “I had been on a few other products over the years and never really had any problems with them, but when I learned about NUWIQ’s formulation – its close resemblance to the F8 produced in the body and its binding affinity to von Willebrand Factor – I knew it was for me. It fits right in with my own philosophies on physical therapy treatment. I have had a great experience with NUWIQ."
Please see NUWIQ Indications and Important Safety Information below.
Mike’s personal experiences with managing the limitations of a bleeding disorder and with successful ways to treat it and enhance his overall health and well-being have inspired him to share his story. “You know, until I was 22 or 23, I really didn’t know anyone else with hemophilia. Getting introduced to the bleeding disorders community, making friends, and getting so much new information was life-changing for me. I want to pass that along.” In 2015 Mike began making presentations for the Hemophilia Federation of America (HFA), continuing that effort since 2022 as a Factor My Way Patient Educator. He has made presentations to people with bleeding disorders in 35 states and counting – and he wants to check all 50 off the list before he’s done. “Having hemophilia taught me to be self-aware, independent, and responsible at an early age. I have turned those lessons to my advantage. Today I want to share everything I have learned and help improve the lives of people with bleeding disorders. It’s my passion and my mission.”
New to Factor My Way? ¿Es nuevo en Factor My Way? Sign up here. Inscríbase aquí.
You are now leaving an Octapharma property. Links to all outside sites are provided as a resource to our visitors. Octapharma disclaims any and all liability for the content, services, or privacy practices of sites that are not owned and operated by Octapharma. Linking to this site is done at your own risk.
To return to the prior page, close this window or select cancel.
To continue to the offsite link, please select continue.
Está abandonando una propiedad de Octapharma. Los enlaces a todos los sitios externos se proporcionan como un recurso para nuestros visitantes. Octapharma no se hace responsable del contenido, los servicios o las prácticas de privacidad de los sitios que no son propiedad de Octapharma ni son operados por Octapharma. Usted visita este sitio por su propia cuenta y riesgo.
Para volver a la página anterior, cierre esta ventana o seleccione Cancelar.
Para continuar al enlace fuera del sitio, seleccione Continuar
Those with Medicare, Medicaid, Medigap, VA, DOD, Tricare or other federal or state government insurance are not eligible to receive co-pay assistance.
Quienes tengan Medicare, Medicaid, Medigap, VA, DOD, Tricare u otro seguro del gobierno federal o estatal no son elegibles para recibir ayuda con los copagos.
We will email you once this event has been scheduled so that you can sign up. Le enviaremos un correo electrónico una vez que este evento haya sido programado para que pueda inscribirse.
Event: Evento:
Date: Fecha:
Presenter: Presentador:
Check your email for event confirmation and participation details from Zoom. You should receive the email within about five minutes. The email will be sent to you by no-reply@zoom.us. If you do not see the confirmation email in your inbox, please check your Spam folder, and if the email is there, mark it as "not spam" and add no-reply@zoom.us to your Address Book. If you can’t locate the email at all, please reach out to your Factor My Way Patient Experience Manager. Revise su correo electrónico para ver la confirmación del evento y los detalles sobre la participación de Zoom. Debería recibir el correo electrónico dentro de aproximadamente cinco minutos. El correo electrónico se enviará desde no-reply@zoom.us. Si no ve el correo electrónico de confirmación en la bandeja de entrada, consulte la carpeta de correo no deseado y, si el correo está allí, máquelo como “no es correo no deseado” y agregue no-reply@zoom.us a su libreta de direcciones. Si no puede encontrar el correo electrónico, comuníquese con el director de Experiencia del Paciente de Factor My Way.
For assistance regarding the following programs, please call the Factor My Way Support Center at 1-855-498-4260. Representatives are available Monday – Friday from
9:00 am – 7:00 pm, EST.
Para obtener ayuda con respecto a los siguientes programas, llame al Centro de soporte de Factor My Way al 1-855-498-4260. Los representantes están disponibles de lunes a viernes, de 9:00 a.m. a 7:00 p.m., EST al 1-855-498-4260.
Already a member? ¿Ya es miembro? Sign-in here Inicie sesión aquí
Thank you for your submission.
Your local Patient Experience Manager will contact you within two to three business days to facilitate your meeting request with Patient Educator .
Gracias por su envío.
Su director de Experiencia del Paciente se comunicará con usted dentro de dos o tres días hábiles para facilitar su solicitud para reunirse con el paciente educador .
This material represents individual patient and/or caregiver experience living with a bleeding disorder.
This content is not intended to be a substitute for professional medical advice, diagnosis or treatment. Please consult with your local Hemophilia Treatment Center physician or other health care provider if you have any questions related to management of bleeding disorders.
Este material representa la experiencia individual de un paciente o cuidador que vive con un trastorno hemorrágico
Este contenido no tiene como objetivo reemplazar el consejo, diagnóstico o tratamiento médico profesional. Consulte con el médico de su Centro de Tratamiento para la Hemofilia local u otro proveedor de atención médica si tiene preguntas relacionadas con el manejo de los trastornos hemorrágicos.
This website uses cookies and stores information on your computer. Some of them are essential to improve our website and your user experience. By using this website, you agree to the use of these cookies. Please check our Data Privacy Statement for more details.
Este sitio web utiliza cookies y almacena información en su computadora. Algunas de ellas son fundamentales para mejorar nuestro sitio web y su experiencia de usuario. Al utilizar este sitio web, acepta el uso de estas cookies. Consulte nuestra Declaración de privacidad de datos para obtener más detalles. Declaración de privacidad de datos para obtener más detalles.
Indications and Important Safety Information for NUWIQ® [Antihemophilic Factor (Recombinant)].
Please see NUWIQ full Prescribing Information. Instructions For Use
Indications and Usage
NUWIQ® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ® is not indicated for the treatment of von Willebrand Disease.
Contraindications
NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.
Warnings and Precautions
Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.
The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).
Adverse Reactions
The most frequently occurring adverse reactions (>5%) in clinical trials were upper respiratory tract infection, headache, fever, cough, lower respiratory tract infection, rhinitis, chills, abdominal pain, arthralgia, anemia, and pharyngitis.
Please see NUWIQ full Prescribing Information. Instructions For Use
Indicaciones e Información de seguridad importante de NUWIQ® [factor antihemofílico (recombinante)].
Consulte la Información de prescripción completa de NUWIQ. Instrucciones de uso
Indicaciones y uso
NUWIQ® es un factor antihemofílico recombinante [factor VIII para la coagulación (factor VIII)] indicado en adultos y niños con hemofilia A para el tratamiento y el control a demanda de los episodios hemorrágicos, el control perioperativo de las hemorragias y profilaxis de rutina con el fin de reducir la frecuencia de los episodios hemorrágicos. NUWIQ® no está indicado para el tratamiento de la enfermedad de von Willebrand.
Contraindicaciones
NUWIQ está contraindicado en pacientes que hayan manifestado reacciones de hipersensibilidad al producto o sus componentes, como anafilaxia, que ponen en riesgo la vida.
Advertencias y precauciones
Es posible que NUWIQ cause reacciones de hipersensibilidad, como anafilaxia. Los primeros signos de reacciones de hipersensibilidad que pueden progresar y derivar en anafilaxia incluyen angioedema, opresión en el pecho, disnea, sibilancias, urticaria o prurito. Si se producen reacciones de hipersensibilidad, suspenda la administración de inmediato e inicie el tratamiento adecuado.
Se pueden formar anticuerpos neutralizantes (inhibidores) del factor VIII luego de administrar NUWIQ. Controle a todos los pacientes para detectar el desarrollo de inhibidores del factor VIII mediante observaciones clínicas y análisis de laboratorio adecuados. Si el nivel del factor VIII en plasma no aumenta según lo esperado o si la hemorragia no se controla luego de la administración de NUWIQ, se debe sospechar la presencia de un inhibidor (anticuerpo neutralizante).
Reacciones adversas
Las reacciones adversas más frecuentes (>5%) que tuvieron lugar en ensayos clínicos fueron infección del tracto respiratorio superior, dolor de cabeza, fiebre, tos, infección del tracto respiratorio inferior, rinitis, escalofríos, dolor abdominal, artralgia, anemia, y faringitis.
Consulte la Información de prescripción completa de NUWIQ. Instrucciones de uso
Indications and Important Safety Information for wilate® [von Willebrand Factor/Coagulation Factor VIII Complex (Human)].
Please see wilate full Prescribing Information.
Indications
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in children and adults with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes in children 6 years of age and older and adults with VWD. wilate® is also indicated in adolescents and adults with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes; and for on-demand treatment and control of bleeding episodes.
Contraindications
wilate® is contraindicated in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reactions, to human plasma-derived products, any ingredient in the formulation, or components of the container.
Warnings and Precautions
Hypersensitivity Reactions
Hypersensitivity reactions may occur with wilate®. Signs and symptoms include angioedema, burning and stinging at the infusion site, chills, flushing, generalized urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, and wheezing that may progress to severe anaphylaxis (including shock) with or without fever. Closely monitor patients receiving wilate® and observe for any symptoms throughout the infusion period.
Because inhibitor antibodies may occur concomitantly with anaphylactic reactions, evaluate patients experiencing an anaphylactic reaction for the presence of inhibitors.
Thromboembolic Events
In VWD, continued treatment using a FVIII-containing VWF product may cause an excessive rise in FVIII activity, which may increase the risk of thromboembolic events. Monitor plasma levels of VWF:RCo and FVIII activities in patients receiving wilate to avoid sustained excessive VWF and FVIII activity levels.
Neutralizing Antibodies
VWD
Hemophilia A
Transmissible Infectious Agents
wilate® is made from human plasma. Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent. There is also the possibility that unknown infectious agents may be present in the product. The risk that wilate® will transmit viruses has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and removing certain viruses during manufacture. Despite these measures, it may still potentially transmit disease.
Record the batch number of the product every time wilate® is administered to a patient, and consider appropriate vaccination (against hepatitis A and B virus) of patients in regular/repeated receipt of wilate®. ALL infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Octapharma USA, Inc., at 1-866-766-4860.
Monitoring and Laboratory Tests
Adverse Reactions
The most common adverse reactions to treatment with wilate (≥ 1%) in patients with VWD were hypersensitivity reactions, urticaria, chest discomfort and dizziness. The most common adverse reactions to treatment with wilate (≥ 1%) in previously treated patients with hemophilia A was pyrexia (fever).
Please see wilate full Prescribing Information.
Indicaciones e Información de seguridad importante de wilate® [complejo de factor de von Willebrand/factor VIII de la coagulación (humanos)].
Consulte la Información de prescripción completa de wilate.
Indicaciones
wilate® es un complejo de factor de von Willebrand/factor VIII de la coagulación (humanos) indicado en niños y adultos con enfermedad de von Willebrand para el tratamiento y el control a demanda de los episodios hemorrágicos, para el control perioperativo de las hemorragias y para profilaxis de rutina con el fin de reducir la frecuencia de los episodios hemorrágicos en niños de 6 años de edad en adelante y adultos con EvW. wilate® también se indica en adolescentes y adultos con hemofilia A para profilaxis de rutina con el fin de reducir la frecuencia de los episodios hemorrágicos; y para el tratamiento y el control a demanda de los episodios hemorrágicos.
Contraindicaciones
wilate® está contraindicado en pacientes con reacciones de hipersensibilidad conocidas, incluidas las reacciones anafilácticas o las reacciones sistémicas graves a productos derivados de plasma humano, cualquier ingrediente de la formulación o los componentes del envase.
Advertencias y precauciones
Reacciones de hipersensibilidad
Pueden producirse reacciones de hipersensibilidad con el uso de wilate®. Los signos y síntomas incluyen angioedema, ardor y picazón en el lugar de la infusión, escalofríos, sofoco, urticaria generalizada, dolor de cabeza, ronchas, hipotensión, letargo, náuseas, inquietud, taquicardia, opresión en el pecho, hormigueo, vómitos y sibilancias que pueden progresar y derivar en anafilaxia grave (incluido shock) con o sin fiebre. Controle de cerca a los pacientes que reciban wilate® y preste atención a cualquier síntoma durante todo el período de infusión.
Debido a que los anticuerpos inhibidores pueden desarrollarse de forma concomitante con las reacciones anafilácticas, evalúe a los pacientes que experimenten una reacción anafiláctica para detectar la presencia de inhibidores.
Eventos tromboembólicos
En la enfermedad de von Willebrand, el tratamiento continuo con un producto de FvW que contiene FVIII puede provocar un incremento excesivo en la actividad del FVIII, y eso puede aumentar el riesgo de eventos tromboembólicos. Controle los niveles en plasma de las actividades del FvW:RCo y el FVIII en los pacientes que reciben wilate para evitar niveles de actividad excesivos y sostenidos del FvW y el FVIII.
Anticuerpos neutralizantes
EvW
Hemofilia A
Agentes infecciosos transmisibles
wilate® está hecho a partir de plasma humano. Debido a que este producto está hecho de sangre humana, puede implicar un riesgo de transmisión de agentes infecciosos, como virus y, en teoría, el agente de la variante de la enfermedad de Creutzfeldt-Jakob (vCJD). También existe la posibilidad de que haya agentes infecciosos desconocidos en el producto. El riesgo de que wilate® transmita virus se ha reducido mediante la realización de pruebas de detección a los donantes de plasma para detectar la exposición previa a determinados virus, mediante análisis para detectar la presencia de ciertas infecciones virales actuales y mediante la desactivación y eliminación de determinados virus durante la fabricación. A pesar de estas medidas, aún existe la posibilidad de que transmita enfermedades.
Registre el número de lote del producto cada vez que wilate® se administre a un paciente y considere aplicar las vacunas adecuadas (contra los virus de la hepatitis A y B) a los pacientes que reciban wilate® de manera regular o repetida. TODAS las infecciones que un médico considere que se pueden haber transmitido a través de este producto deben ser informadas por el médico u otro proveedor de atención médica a Octapharma USA, Inc., al 1-866-766-4860.
Control y análisis de laboratorio
Reacciones adversas
Las reacciones adversas más comunes al tratamiento con wilate (≥ 1%) en pacientes con enfermedad de von Willebrand fueron reacciones de hipersensibilidad, urticaria, malestar en el pecho y mareos. La reacción adversa más común al tratamiento con wilate (≥ 1%) en pacientes con hemofilia A previamente tratados fue pirexia (fiebre).
Consulte la Información de prescripción completa de wilate.
|
|
|
|
© 2025 Octapharma USA, Inc.
All Rights Reserved
Todos los derechos reservados
|